Clinical Trial Update: Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients [Phase 1]

View source ↗

Summary

Phase I trial evaluating Icaritin, a novel estrogen receptor a36 modifier, in patients with metastatic breast cancer; the study status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Icaritin (icaritin)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Metastatic Breast Cancer | Phase 1 | Status: UNKNOWN